{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"}],"units":"Participants"}],"description":"Grade 3-4 Bearman non-hematologic toxicity will be carefully monitored throughout this study. The protocol will be terminated due to safety concerns if there exists sufficient evidence suggesting that the true rate of grade 3-4 nonhematologic toxicity exceeds 25%. All patients, regardless of histology, will be evaluated together for purposes of toxicity. Sufficient evidence will be taken to be a lower limit to the appropriate 90% one-sided confidence interval in excess of 25%","groups":[{"description":"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.\n\nCHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.\n\nAUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0.\n\ncyclophosphamide: Given IV\n\netoposide: Given IV\n\niodine I 131 tositumomab: Given IV\n\nquality-of-life assessment: Ancillary study\n\nperipheral blood stem cell transplantation: Undergo ASCT given via central catheter","id":"OG000","title":"Treatment (Radio Labeled Monoclonal Antibody, Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Number of Grade 3-4 toxicities.","reportingStatus":"POSTED","timeFrame":"From date of first exposure to study drug, through date of relapse/progression or other significant medical event confounding further assessment, assessed up to 15 years","title":"Toxicity as Assessed by Common Terminology Criteria (CTC) v 2.0","type":"SECONDARY","unitOfMeasure":"events"}